Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2009

View Archived Issues

Abbott presents business highlights of first quarter

Study provides proof-of-concept of ChronVac vaccination for hepatitis C

Data backing clinical investigation of ANA-773 in hepatitis C presented

Janssen describes novel inhibitors of MDM2 and p53 interaction

Novel heat shock protein 90 inhibitors claimed by Vernalis for cancer treatment

Santen claims glucocorticoid receptor agonists for ocular inflammatory conditions

Alkylsulfone derivatives claimed by Daiichi Sankyo for the treatment of Alzheimer's disease

Taisho presents novel heterocyclic compounds for the treatment of pain

Novel inhibitor of p21-activated kinase disclosed by Pfizer with potential use as anticancer agent

Phase I data show responses in one-third of solid cancer patients given MKC-1106-PP immunotherapy

NanoBio initiates FDA approved adjuvanted intranasal influenza vaccine trial

FDA issues complete response to Discovery Labs regarding Surfaxin NDA in RDS

Galapagos and Opsona Therapeutics enter drug discovery collaboration

Isotechnika reports 12-month follow-up data from phase IIb PROMISE trial

Merck & Co., Medarex and MBL sign exclusive agreement

Novel humanized antibody with in vivo antitumor activity developed by Epitomics

Dendreon begins phase I trial of D-3263 in advanced cancer

EMD Serono identifies new pyridazinone c-MET kinase inhibitors

Circassia's initiates phase II ToleroMune trial in asthma patients

Melanin-concentrating hormone system may play role in addiction

Sanofi pasteur initiates clinical studies tetravalent dengue vaccine in Singapore and Vietnam

QRxPharma successfully completes phase III pilot study of MoxDuo IR

Health Canada approves Photocure's Metvix in combination with Aktilite for AK and sBCC

Alkermes presents update on the clinical development of Vivitrol

ImQuest and Arisyn receive phase I SBIR grant from NIH to develop HCV inhibitor

Welichem begins IND-enabling toxicology studies for WBI-1001

Transave completes enrollment in Arikace phase II bronchiectasis study

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026